Analyst Patrick Wood from Morgan Stanley maintained a Hold rating on Alphatec Holdings and keeping the price target at $16.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Patrick Wood has given his Hold rating due to a combination of factors that balance both positive and cautious elements in Alphatec Holdings’ performance and outlook. The company has shown impressive growth, exceeding expectations in Q3 with a 30% increase, and continues to gain market share. This growth is supported by strong rep hiring and upcoming catalysts like the Valence launch and advancements in deformity solutions.
Despite these positive developments, Wood remains cautious, noting that while the company is moving towards profitability with positive free cash flow, it is still in the early stages of this transition. The upcoming catalysts in 2026, including new product launches and opportunities to de-lever the balance sheet, present potential for future growth, but these are longer-term prospects. Therefore, the Hold rating reflects a balanced view of the current achievements and future uncertainties, suggesting investors may want to wait for more consistent profitability and execution of future plans before taking a more aggressive stance.
Wood covers the Healthcare sector, focusing on stocks such as TransMedics Group, Becton Dickinson, and Medtronic. According to TipRanks, Wood has an average return of -0.5% and a 52.90% success rate on recommended stocks.
In another report released on October 22, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $15.50 price target.